Atlas company financials

Immunovant, Inc.

Standardized 3-year financial series for Immunovant, Inc., built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0001764013FY2022 → FY2024

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2024

Revenue

$24.9M

Adjusted EBITDA

—

Net result

-$259.3M

Net financial debt

—

Latest source: FY2024 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$8.9M

TTM revenue

$19.5M

TTM free cash flow

—

Latest quarter net result

-$51.4M

Quarterly coverage: 8 periods · latest quarter FY2023-Q3 · TTM revenue growth 1591.0%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
primary · immunovant-inc-fy2022 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2023-05-22 · Retrieved: 2026-04-26T11:52:25.658905+00:00
SEC EDGAR companyfacts
us-gaap:ResearchAndDevelopmentExpense · us gaap companyfacts · primary · immunovant-inc-fy2022 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2022-06-08 · Retrieved: 2026-04-26T11:52:25.658905+00:00
SEC EDGAR companyfacts
primary · immunovant-inc-fy2024 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2024-05-29 · Retrieved: 2026-04-26T11:52:25.658905+00:00
SEC EDGAR companyfacts
primary · immunovant-inc-fy2021-q2 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2022-11-04 · Retrieved: 2026-04-26T11:52:25.658905+00:00
SEC EDGAR companyfacts
us-gaap:ResearchAndDevelopmentExpense · us gaap companyfacts · primary · immunovant-inc-fy2021-q2 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2021-11-05 · Retrieved: 2026-04-26T11:52:25.658905+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2022	0	—	—	-157M	-106M	-254K	—	missing adjusted ebitda · missing cost of revenue · missing ebit · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing sg and a
FY2023	8M	—	—	-211M	-188M	-197K	—	missing adjusted ebitda · missing cost of revenue · missing ebit · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing research and development · missing sg and a
FY2024	25M	—	—	-259M	-214M	-360K	—	missing adjusted ebitda · missing cost of revenue · missing ebit · missing gross profit · missing interest expense · missing inventory · missing net financial debt · missing research and development · missing sg and a

Filing provenance

Every year stays linked back to its source document.

FY2022partial

SEC EDGAR companyfacts · XBRL · consolidated_reported

missing_adjusted_ebitda · missing_cost_of_revenue · missing_ebit · missing_gross_profit · missing_interest_expense · missing_inventory · missing_net_financial_debt · missing_sg_and_a

Open official source filing

FY2023partial

SEC EDGAR companyfacts · XBRL · consolidated_reported

missing_adjusted_ebitda · missing_cost_of_revenue · missing_ebit · missing_gross_profit · missing_interest_expense · missing_inventory · missing_net_financial_debt · missing_research_and_development · missing_sg_and_a

Open official source filing

FY2024partial

SEC EDGAR companyfacts · XBRL · consolidated_reported

Open official source filing

Immunovant, Inc.

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

A proof-of-concept company data surface, not a dead PDF shelf.

Official links first, raw iterFact payloads right next to them.

Official sources

Headline company financials by fiscal year

Every year stays linked back to its source document.

iterFact raw links

Methodology

Data vintage